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Abstract
Purpose: Elevated ferritin levels are associated with poor outcomes in Covid-19 patients. Optimal timing of ferritin assessment
and the merit of longitudinal values remains unclear. Methods: Patients admitted to Henry Ford Hospital with conﬁrmed SARSCoV-2 were studied. Regression models were used to determine the relation between ferritin and mortality, need for mechanical
ventilation, ICU admission, and days on the ventilator. Results: 2265 patients were evaluated. Patients with an initial ferritin of >
490 ng/mL had an increased risk of death (OR 3.4, P < .001), admission to the ICU (OR 2.78, P < .001) and need for mechanical
ventilation (OR 3.9, P < .001). There was no difference between admission and Day 1 ICU ferritin levels (611.5 ng/mL vs. 649 ng/
mL respectively; P = .07). The decline in ferritin over ICU days 1-4 was similar between survivors and non-survivors. A change in
ferritin levels from admission to ICU Day 1 (P = .330), or from ICU Day 1 to 2 (P = .788), did not predict days on the ventilator.
Conclusions: Initial Ferritin levels were highly predictive of ICU admission, the need for mechanical ventilation and in-hospital
mortality. However, longitudinal measures of ferritin throughout the hospital stay did not provide additional predictive value.
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Introduction
The world witnessed the emergence of a novel virus, severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), in late
December 2019. To date, there have been more than 360 million
reported cases of Covid-19, the respiratory infection caused by
SARS-CoV-2, with more than 5 million deaths worldwide.1
The spectrum of illness caused by SARS-CoV-2 ranges from
asymptomatic infection to severe pneumonia with acute respiratory disease syndrome (ARDS) and multiple organ dysfunction
syndrome (MODS).2 Factors contributing to the severity of
illness include increased age, male gender, pre-existing comorbidities, obesity, pregnancy and immunosuppression.3
Several biomarkers have been associated with the severity of
illness including elevation in C-reactive protein (CRP), procalcitonin, D-Dimer and ferritin.4 Ferritin elevation in patients
with severe COVID-19 has been thought to represent uncontrolled inﬂammation and massive cytokine release, similar to
that observed in hemophagocytic lymphohistiocytosis (HLH)
or Macrophage Activation Syndrome (MAS).5,6 In one report,
ferritin levels above 300 nanograms per milliliter (ng/mL)
were associated with ARDS development with a hazard ratio
(HR) of 3.53 (1.52-8.16).7 Meta-analyses have supported the
association between high ferritin level and poor outcome
from SARS-CoV-2 infection.3,4,8–10
While ferritin appears to be associated with in-hospital mortality in patients with Covid-19, knowledge gaps remain

pertaining to the optimal timing of ferritin assessment and the
value of longitudinal assessments of ferritin in the clinical
course of SARS-CoV-2 infection evolves.7
Although clinical data lack a compelling rationale for the
longitudinal evaluation of these biomarkers, they have been
routinely followed in many centers (including ours) with the
premise that changes over time may be predictive of clinical
course and outcomes.8 However, there is no evidence to
support a beneﬁt to the longitudinal assessment of ferritin as
a tool to predict respiratory decline and mortality in patients
admitted to the hospital with COVID −19. The goal of this
study was to evaluate the relationship between admission ferritin levels and outcomes in our large, urban medical center and
to assess whether longitudinal assessment of ferritin levels
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would predict intensive care unit (ICU) admission, acute respiratory failure requiring intubation and mechanical ventilation,
and mortality.

Methods
Study Population
We conducted a retrospective cohort study of patients admitted
to Henry Ford Hospital- Detroit Campus for COVID-19 infection between March 7, 2020 and May 11, 2021. The study protocol was approved by the institutional review board. Patient
consent was waived because of the retrospective design and
inclusion of deceased patients. The study included adults over
the age of 18 years who were admitted to the hospital with a
laboratory-conﬁrmed SARS-CoV-2 infection diagnosed using
quantitative reverse transcriptase-polymerase chain reaction.
The admission ferritin level was deﬁned as the initial ferritin
drawn within the ﬁrst 24 h of admission.

ventilation and ICU admission. The variables used in these
analyses included ferritin at the cut off determined by ROC
curve analysis, race/ethnicity, sex, median income by zip
code, body mass index (BMI), chronic obstructive pulmonary
disease/asthma, diabetes mellitus, congestive heart failure
(CHF), and chronic kidney disease (CKD). Variables with a p
value of less than or equal to 0.1 were included in the multivariate regression models.
To examine the changes in ferritin levels over time among
those who lived or died, a mixed model was used, which
included the effects of time, mortality and the interaction
between time and mortality.
For those patients in the ICU, simple linear regression was
used to test if changes in ferritin levels over time signiﬁcantly
predicted the duration of mechanical ventilation.
Dichotomous variables were assigned to each biomarker:
CRP (positive ≥10 mg/L) or negative, Procalcitonin positive
(> 0.5 ng/mL) or negative, or d-dimer (positive ≥ 1.4 mcg/
mL) or negative.

Statistical Analysis
Continuous variables were compared using the student t test or
the Kruskal-Wallis rank-sum test in the cases of nonnormally
distributed variables and expressed, respectively, as means ±
SD or median and interquartile range. Categorical variables
were expressed as percentages and analyzed using a
chi-squared test. A receiver operating characteristic (ROC)
curve was used to test the ability of the admission ferritin
level to predict in-hospital mortality. The optimal cut point
(Liu, 2012) was used as a dichotomous variable to predict outcomes in this study.
We used univariate logistic regression to identify independent risk factors for mortality, and need for mechanical

Results
2265 patients were admitted to the hospital with COVID-19
between March 2020 and May 2021. Of these, 700 patients
(31%) required an ICU admission and 284 patients (12.5%)
died. Of the total number of patients admitted, 1904 patients
(84%) had a documented ferritin level within the ﬁrst 24 h of
admission. The median ferritin level for the 1904 patients
who had a ferritin drawn within 24 h of hospital admission
was 417 (95% CI 181-857). Patients with and without an admission ferritin level had similar baseline demographics and
co-morbidities including age, gender, BMI, Charlson comorbidity index9 and a medical history of COPD/ Asthma,

Table 1. Patient Characteristics.

Median Ferritin, ng/mL
Age, SD
Male
POC
Median BMI
Comorbid conditions
COPD/ Asthma
Hypertension
Diabetes
CHF
Chronic kidney disease
Median Charlson Comorbidity index
Inpatient medications
Glucocorticoids
Antibiotics
Tociluzimab
Remdesivir
ICU admission
In hospital mortality

No Admission Ferritin
N = 361

Ferrin drawn
N = 1904

P value

N/A
59.5 ± 17.2
180 (49.9)
240 (66.5)
30.2 (25.5-36.1)

417 (181-857)
60.5 ± 16.1
955 (50.1)
1567 (82.3)
31.0 (26.5-37.1)

.427
.911
<.001
.09

75 (20.8)
246 (68.1)
138 (38.2)
23 (6.4)
94 (26)
3 (2-6)

385 (20.2)
1340 (70.4)
842 (45.2)
124 (6.5)
412 (21.6)
3 (1-5)

.810
.396
.035
.920
.066
<.001

169 (46.8)
201 (55.7)
12 (3.32)
68 (18.8)
126 (34.9)
50 (13.9)

1494 (78.5)
1038 (54.5)
69 (3.6)
685 (36)
574 (30.2)
234 (12.3)

<.001
.684
.778
<.001
.073
.412
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hypertension, CHF, and CKD (Table 1). Patients without an
admission ferritin were less likely to have diabetes (38.2% vs.
45.2%, p 0.035), and more likely to have received glucocorticoids (78.5% vs. 46.8% P < .001) and Remdesivir (36% vs.
18.8%, P < .001). Both groups had similar mortality and ICU
admission rates (13.9% vs. 12.3%, P = .412) and (34.9% vs.
30.2%, P = .073) respectively.
Generation of a ROC curve for predicting hospital mortality
identiﬁed an optimal cutoff of admission ferritin level of 490
(AUC 0.65; sensitivity .65 and speciﬁcity 0.58). (Figure 1).
Patients with an initial ferritin of > 490 ng/mL had an
increased risk of death (OR 3.4; 95%CI 2.45 to 4.76, P <
.001) and increased risk of admission to the ICU (OR 2.78;
95% CI 2.26 to 3.41, P < .001). Moreover, in those patients
admitted to the ICU, ferritin was a strong predictor of requiring
mechanical ventilation (OR 3.9 [2.98 to 5.17], P < .001)
(Table 2).
Of the 1859 patients initially admitted to an inpatient service,
294 patients required transfer to the ICU. These patients had a
higher admission ferritin levels (594 ng/mL [95% CI 275 to
1126]) compared to the patients who did not require ICU transfer (360.5 ng/mL [95% CI 156 to 737]). Moreover, among the
patients who were transferred to the ICU, a higher admission
ferritin level (above 490 ng/ml) was associated with a more
rapid need for transfer to the ICU setting (hazard ratio 2.0 [CI
1.5 to 2.6]; P < .001) (Figure 2) (Tables 3 and 4).
Among patients admitted directly to the ICU or transferred to
the ICU from another inpatient unit, the ICU day 1 ferritin
levels were not signiﬁcantly different from the admission ferritin levels (649 ng/mL [95% CI 308 −1232] vs. 611.5 ng/mL
[95% CI 287 to 1126] respectively; P = .07). Ferritin levels
were signiﬁcantly higher in those who died during ICU days
1-4.
While both survivors and non-survivors experienced a
decrease in ferritin over days 1-4, the extent of decline in ferritin
levels was similar between these 2 groups (Figure 3). This
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suggests that a change in ferritin over the ﬁrst 96 h of ICU
care did not provide additional prognostic information (interaction p-value = 0.4562).
Similarly, in patients requiring mechanical ventilation, a
change in ferritin levels from admission to ICU day 1 (regression coefﬁcient −0.0003 [95% CI −0.001 to −0.003], P =
.330), or from ICU day 1 to ICU day 2 (regression coefﬁcient
−0.00066 [95% CI −0.0005 to −0.0004];, P = .788), did not
predict number of days requiring mechanical ventilation.
In addition to ferritin, other biomarkers were found to be signiﬁcant predictors of mortality when elevated (CRP: OR 2.1
([1.57-2.82], P < .001), Procalcitonin: OR 3.76 ([2.7-5.1], P <
.001) and D-Dimer: OR 3.2 ([2.3-4.4], P < .001)). (Table 5)
Finally, 977 patients had an elevated serum ferritin > 490 ng/
mL at time of admission even when CRP, procalcitonin and
D-Dimer levels were negative; this also predicted mortality
(adjusted OR 3.19 [2.21-4.59]; P < .0001).

Discussion
The primary ﬁnding of this study was that, in hospitalized
patients with COVID-19, ferritin levels obtained within 24 h
of admission were highly predictive of ICU admission, the
need for mechanical ventilation and in-hospital mortality. The
predictive ability of admission ferritin levels was also not
dependent on clinical status at the time of admission; ferritin
predicted outcomes equally well in patients requiring direct
ICU admission and admission to a general medical ward
(non-ICU) at the time of presentation.
Longitudinal measures of ferritin throughout the hospital
stay did not provide additional predictive value for respiratory
deterioration or mortality in our population. While ferritin
levels were higher in non survivors across all 4 days in the
ICU, changes in ferritin levels over this time period was not predictive of in hospital mortality. Indeed, the absolute admission
value of ferritin was more closely associated with clinical deterioration than the rate of change in ferritin. Thus, the admission
ferritin level might have clinical utility in the initial risk stratiﬁcation and triage of patients presenting with COVID-19, but
repeated measurements are of limited value. These results are
consistent with the results of a prior study of 235 patients
showing that daily ferritin levels did not predict length of
ICU stay.10 To our knowledge, this is the largest study
Table 2. Predictors of in-Hospital Mortality.
Factor

Figure 1. Receiver operating characteristic curve (ROC)
demonstrating the ability of ferritin level to predict in-hospital
mortality. The optimal discriminatory cutoff point corresponded to a
ferritin level of 490 ng/mL. Area under the ROC curve 0.65.

Ferritin > 490 ng/mL
Male
Age > 65
BMI
History HTN
History DM
History CHF
History CKD

Adjusted OR

P value

3.41 (2.45-4.76)
1.27 (0.95-1.70)
3.38 (2.45-4.68)
1.00 (0.985-1.02)
0.91 (0.624-1.33)
1.20 (0.90-1.61)
1.66 (0.990-2.80)
1.15 (0.83-1.59)

<.001
.111
<.001
.782
.624
.212
.055
.411

4

Journal of Intensive Care Medicine 0(0)
Table 5. Biomarkers as Predictors of in-Hospital Mortality.
Biomarker
Ferritin > 490
CRP > 10
Procalcitonin positive
D-Dimer > 1.4

Figure 2. Probability of requiring transfer from general ward to ICU
was higher among those patients with an admission ferritin level > 490
(solid line) compared to patients with a level < 490 (dashed line)
(hazard ratio 2.0 [CI 1.5 to 2.6]; P < .001).

Table 3. Predictors of ICU Admission.
Factor

Adjusted OR

P value

Ferritin > 490 ng/mL
Male
Age > 65
History DM

2.78 (2.26-3.41)
1.06 (0.87-1.29)
1.28 (1.05-1.55)
1.52 (1.25-1.84)

<.001
.575
.013
<.001

Table 4. Predictors of Mechanical Ventilation.
Factor
Ferritin > 490 ng/mL
Male
Age > 65
History HTN
History DM
History CHF

Adjusted OR

P value

3.92 (2.98-5.17))
1.18 (0.93-1.50)
1.52 (1.19-1.94)
1.02 (0.76-1.37)
1.50 (1.18-1.91)
1.63 (1.05-2.52)

<.001
.179
.001
.907
.001
.029

Figure 3. Overall, median ferritin levels were higher among
non-survivors, but the decline in ferritin levels over the ﬁrst 4 days in
the ICU was similar between survivors (Circle) and non-survivors
(Square) (interaction P-value = .4562).

Unadjusted OR

Adjusted OR

P

3.88 (2.8-5.3)
2.0 (1.5-2.63)
4.2 (3.2-5.7)
4.1 (3.0-5.6)

3.41 (2.45-4.76)
2.1 (1.57-2.82)
3.76 (2.7-5.1)
3.2 (2.3-4.4)

<.001
<.001
<.001
<.001

evaluating the association between serial measurements of ferritin levels and mortality in hospitalized patients with
COVID-19.
Ferritin has previously been shown to be a predictor of poor
outcomes11,12 in patients with COVID-19. One meta-analysis
of 25 studies and 5350 patients found that a higher serum ferritin level was independently associated with ARDS, mortality,
and severe COVID-19.4 Another meta-analysis included 189
studies with data from 57 563 COVID-19 patients and
showed signiﬁcant differences in mean ferritin levels between
survivors and non-survivors.13
Not all studies have found correlations between ferritin and
mortality. One early report showed that elevated ferritin levels
were associated with development of ARDS, but not with
death.14 Another study demonstrated that ferritin levels over
the 25th percentile were associated with more severe pulmonary
involvement but not with outcomes.15 Finally, a retrospective
study evaluated 942 COVID-19 patients and showed that
neither presentation ferritin levels nor the maximum value
over the duration of hospitalization was associated with allcause mortality, new mechanical ventilation, or a new renal
replacement therapy requirement.16
Ferritin is known to be elevated in inﬂammatory conditions,
both as an acute-phase reactant and as a marker for developing a
cytokine storm.17 The pathogenesis of COVID-19 has been
shown to have similarities with macrophage activating syndrome and catastrophic antiphospholipid syndrome.18 Similar
to other viral infections, iron metabolism helps support the
innate immune system during the early and acute phases of
SARS-CoV-2 infection by decreasing the iron bioavailability
and replication of the virus.19 While other inﬂammatory diseases have shown ferritin levels in excess of 1000 ng/mL to
be associated with mortality, others have shown that a level >
300 ng/mL leads to worsening outcomes.20–24 This is consistent
with our study in which ROC analysis indicated a cutoff of
490 ng/mL to predict in-hospital mortality.
We found that CRP, D-Dimer and procalcitonin were also
predictive of in-hospital mortality. These ﬁndings are in agreement with other studies that found an association between
inﬂammatory markers and poor outcomes in patients with
COVID-19.25–28 However, in contrast to ferritin, CRP, procalcitonin and D-Dimer levels are commonly incorporated into
clinical decision making. For example, serum procalcitonin
has value in decisions to deescalate antibiotics in patients
with bacterial infections and to initiate antibacterial antibiotics
in speciﬁc patients.29,30 A D-Dimer is frequently obtained as
part of the clinical assessment for presence of venous
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thromboembolism31 and more recently has been used to guide
anticoagulation treatment in patients with COVID-19.32
Finally, serum CRP has been used to stratify patients for tocilizumab in severe COVID-19.33 In contrast to these biomarkers,
ferritin is not used to guide speciﬁc management or treatment
strategies in patients with COVID-19. In addition, the utility
of ferritin as a predictor of poor outcome was independent of
the values of the other inﬂammatory makers; a substantial
number of patients had ferritin elevations > 490 in the
absence of an elevated CRP, D-dimer or procalcitonin. This
ﬁnding suggests that ferritin serves as an independent predictor
of deterioration and death in patients hospitalized with severe
COVID-19. Notably, these other biomarkers might predict
poor outcomes because they identify cohorts of patients
enriched for secondary clinical processes such as venous thromboembolism or bacterial superinfection.
There are a few limitations in our study. First, this is a singlecenter retrospective study performed in a large, urban, tertiarycare hospital. The results may not be broadly applicable in other
clinical settings. Since ferritin levels were known to the primary
team, it is feasible that patient care was approached differently
for patients with different ferritin levels; however, as discussed,
absolute ferritin levels in patients with Covid-19 infection have
not led to speciﬁc medical interventions. Finally, there was no
validation cohort for the ferritin cutoff of 490. Future studies
could be aimed at validating this cutoff value in a separate
group of patients.
In conclusion, our retrospective study demonstrates a strong
association between the admission ferritin level, ICU admission, need for mechanical ventilation and ultimate mortality
in patients with COVID-19 infection. Importantly, this predictive value was independent of other commonly used biomarkers
and was not enhanced by longitudinal assessments. Together,
these data support the clinical value of a single measurement
of ferritin at the time of hospital admission for the purposes
of risk-stratiﬁcation while also demonstrating the lack of
value in serial assessments.
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